Table 3.
Monotherapy and combination therapy prescribed to the respondents (n = 310).
| Drug Therapy | Frequency | Percentage (%) |
|---|---|---|
| Monotherapy | 8 | 2.58 |
| Simvastatin | 4 | 50.00 |
| Amlodipine | 3 | 37.50 |
| Atorvastatin | 1 | 12.50 |
| Combination therapy | 302 | 97.42 |
| List of top 10 combination therapy | ||
| Amlodipine + simvastatin | 17 | 5.63 |
| Simvastatin + perindopril + amlodipine + metformin | 10 | 3.31 |
| Perindopril + amlodipine + simvastatin | 8 | 2.65 |
| Amlodipine + simvastatin + metformin | 8 | 2.65 |
| Metformin + gliclazide + simvastatin + amlodipine + perindopril | 6 | 1.99 |
| Perindopril + amlodipine + simvastatin + mecobalamin | 4 | 1.32 |
| Metformin + simvastatin + amlodipine + gliclazide | 4 | 1.32 |
| Amlodipine + perindopril + simvastatin + aspirin | 4 | 1.32 |
| Perindopril + simvastatin | 3 | 0.99 |
| Simvastatin + amlodipine, metformin + gliclazide + perindopril + hydrochlorothiazide | 3 | 0.99 |
| Other combinations | 235 | 77.81 |